View Future GrowthBlack Bird Biotech 과거 순이익 실적과거 기준 점검 0/6지난 몇 년간 Black Bird Biotech 의 실적에 대한 데이터가 부족합니다.핵심 정보n/a순이익 성장률n/a주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률5.95%매출 성장률n/a자기자본이익률n/a순이익률n/a최근 순이익 업데이트30 Sep 2023최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 18Black Bird Biotech, Inc. announced delayed 10-Q filingOn 05/16/2024, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Apr 17+ 1 more updateBlack Bird Biotech, Inc. Appoints Nelson Grist as New CEOBlack Bird Biotech, Inc. announced that it has appointed public markets veteran Nelson Grist as its Chief Executive Officer (CEO). With over 15 years of experience in executive positions at publicly traded companies focused on emerging technologies in a variety of industries, Grist seeks to expand the Company’s strategic growth plan beyond its current agricultural offerings into burgeoning verticals such as innovative wellness and healthcare solutions through both organic growth and M&A activities. Mr. Grist has over 15 years’ experience serving in a Chief Executive Officer role at multiple publicly-traded companies focused on the health and wellness sector. Beyond his leadership roles in capital markets, Mr. Grist has extensive experience as a global CPG (customer packaged goods) and direct selling industry executive with progressive international leadership and general management experience across North America, Latin America, and Europe. He is a proven transformational leader, strategic thinker, and change agent, with a track record of creating shareholder value through profitable growth, brand development, performance improvement and team building. Mr. Grist’s experience also extends into the areas of P&L management, organizational design, consumer marketing, commercial capability enhancement, supply chain, talent development, and bringing cross-functional work groups together with a common goal to produce outstanding results.공시 • Apr 02Black Bird Biotech, Inc. announced delayed annual 10-K filingOn 04/01/2024, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Nov 17Black Bird Biotech, Inc. announced delayed 10-Q filingOn 11/15/2023, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • May 16Black Bird Biotech, Inc. announced delayed 10-Q filingOn 05/15/2023, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Aug 17Black Bird Biotech, Inc. announced delayed 10-Q filingOn 08/16/2022, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • May 17Black Bird Biotech, Inc. announced delayed 10-Q filingOn 05/16/2022, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Apr 13William J. Lobell Appoints as Executive Vice President of Sales and Development for Black Bird Biotech, IncOn April 7, 2022, William J. LoBell was appointed as Executive Vice President of Sales and Development for Black Bird Biotech, Inc. From December 2021 until April 2022, Mr. LoBell served as a consultant to Barry's Restore It All Products.공시 • Apr 01Black Bird Biotech, Inc. announced delayed annual 10-K filingOn 03/31/2022, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Aug 17Black Bird Biotech, Inc. announced delayed 10-Q filingOn 08/16/2021, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • May 18Digital Development Partners, Inc. announced delayed 10-Q filingOn 05/17/2021, Digital Development Partners, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Apr 02Digital Development Partners, Inc. announced delayed annual 10-K filingOn 03/31/2021, Digital Development Partners, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Feb 10Digital Development Partners, Inc. Obtains Exclusive Worldwide Distribution Rights and 80% Reduction in Royalty Rate to Disruptive EPA Registered Plant-Based Biopesticide MiteXstreamDigital Development Partners, Inc. announced that it has obtained the exclusive worldwide distribution rights and an 80% reduction in the royalty rate to the disruptive plant-based biopesticide MiteXstream, an effective eradicator of spider mites, a pest that destroys crops, especially cannabis, hops, coffee, and house plants, as well as molds and mildew. Spider Mites are an industry wide issue. In fact, in addition to cannabis, spider mites are a significant pest in the production of hemp and hops, among other agricultural products. MiteXstream eliminates spider mites and their eggs, with no risk of plant damage. Based upon independent lab testing, users of MiteXstream are able to treat their cannabis plants through the day of harvest and still satisfy state-level pesticide testing standards, creating a tremendous competitive advantage, the MiteXstream secret sauce.공시 • Nov 17Digital Development Partners, Inc. announced delayed 10-Q filingOn 11/16/2020, Digital Development Partners, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Aug 19Digital Development Partners, Inc. announced delayed 10-Q filingOn 08/18/2020, Digital Development Partners, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.매출 및 비용 세부 내역Black Bird Biotech가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:BBBT 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비30 Sep 230-10030 Jun 230-10031 Mar 230-11031 Dec 220-21030 Sep 220-22030 Jun 220-32031 Mar 220-22031 Dec 210-21030 Sep 210-11030 Jun 210-11031 Mar 210-11031 Dec 200-11030 Sep 20000030 Jun 20000031 Mar 20000031 Dec 190000양질의 수익: BBBT가 고품질 수익을 갖고 있는지 판단하기에는 데이터가 부족합니다.이익 마진 증가: 지난 1년 동안 BBBT의 이익률이 개선되었는지 판단하기에 데이터가 부족합니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 지난 5년 동안 BBBT의 연간 수익 성장률이 양(+)이었는지 판단하기에 데이터가 부족합니다.성장 가속화: BBBT의 지난해 수익 성장률을 5년 평균과 비교하기에 데이터가 부족합니다.수익 대 산업: BBBT의 지난 해 수익 증가율이 Pharmaceuticals 업계 평균을 상회했는지 판단하기에 데이터가 부족합니다.자기자본이익률높은 ROE: BBBT는 현재 수익성이 없으므로 자본 수익률이 음수(0%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/24 05:33종가2026/05/21 00:00수익2023/09/30연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Black Bird Biotech, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • May 18Black Bird Biotech, Inc. announced delayed 10-Q filingOn 05/16/2024, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Apr 17+ 1 more updateBlack Bird Biotech, Inc. Appoints Nelson Grist as New CEOBlack Bird Biotech, Inc. announced that it has appointed public markets veteran Nelson Grist as its Chief Executive Officer (CEO). With over 15 years of experience in executive positions at publicly traded companies focused on emerging technologies in a variety of industries, Grist seeks to expand the Company’s strategic growth plan beyond its current agricultural offerings into burgeoning verticals such as innovative wellness and healthcare solutions through both organic growth and M&A activities. Mr. Grist has over 15 years’ experience serving in a Chief Executive Officer role at multiple publicly-traded companies focused on the health and wellness sector. Beyond his leadership roles in capital markets, Mr. Grist has extensive experience as a global CPG (customer packaged goods) and direct selling industry executive with progressive international leadership and general management experience across North America, Latin America, and Europe. He is a proven transformational leader, strategic thinker, and change agent, with a track record of creating shareholder value through profitable growth, brand development, performance improvement and team building. Mr. Grist’s experience also extends into the areas of P&L management, organizational design, consumer marketing, commercial capability enhancement, supply chain, talent development, and bringing cross-functional work groups together with a common goal to produce outstanding results.
공시 • Apr 02Black Bird Biotech, Inc. announced delayed annual 10-K filingOn 04/01/2024, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Nov 17Black Bird Biotech, Inc. announced delayed 10-Q filingOn 11/15/2023, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • May 16Black Bird Biotech, Inc. announced delayed 10-Q filingOn 05/15/2023, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Aug 17Black Bird Biotech, Inc. announced delayed 10-Q filingOn 08/16/2022, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • May 17Black Bird Biotech, Inc. announced delayed 10-Q filingOn 05/16/2022, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Apr 13William J. Lobell Appoints as Executive Vice President of Sales and Development for Black Bird Biotech, IncOn April 7, 2022, William J. LoBell was appointed as Executive Vice President of Sales and Development for Black Bird Biotech, Inc. From December 2021 until April 2022, Mr. LoBell served as a consultant to Barry's Restore It All Products.
공시 • Apr 01Black Bird Biotech, Inc. announced delayed annual 10-K filingOn 03/31/2022, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Aug 17Black Bird Biotech, Inc. announced delayed 10-Q filingOn 08/16/2021, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • May 18Digital Development Partners, Inc. announced delayed 10-Q filingOn 05/17/2021, Digital Development Partners, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Apr 02Digital Development Partners, Inc. announced delayed annual 10-K filingOn 03/31/2021, Digital Development Partners, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Feb 10Digital Development Partners, Inc. Obtains Exclusive Worldwide Distribution Rights and 80% Reduction in Royalty Rate to Disruptive EPA Registered Plant-Based Biopesticide MiteXstreamDigital Development Partners, Inc. announced that it has obtained the exclusive worldwide distribution rights and an 80% reduction in the royalty rate to the disruptive plant-based biopesticide MiteXstream, an effective eradicator of spider mites, a pest that destroys crops, especially cannabis, hops, coffee, and house plants, as well as molds and mildew. Spider Mites are an industry wide issue. In fact, in addition to cannabis, spider mites are a significant pest in the production of hemp and hops, among other agricultural products. MiteXstream eliminates spider mites and their eggs, with no risk of plant damage. Based upon independent lab testing, users of MiteXstream are able to treat their cannabis plants through the day of harvest and still satisfy state-level pesticide testing standards, creating a tremendous competitive advantage, the MiteXstream secret sauce.
공시 • Nov 17Digital Development Partners, Inc. announced delayed 10-Q filingOn 11/16/2020, Digital Development Partners, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Aug 19Digital Development Partners, Inc. announced delayed 10-Q filingOn 08/18/2020, Digital Development Partners, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.